AI-QSP: Transforming Drug Discovery
BiotechX Basel 2025
Prof. Igor Goryanin & Dr Oleg Demin
The Challenge
Clinical trial attrition remains above 85%, with Phase II as the critical bottleneck. Each late-stage failure costs hundreds of millions, eroding portfolio value and delaying patient access to life-saving treatments.
The Urgency
Regulatory pressure from FDA/EMA, payer demands for efficiency, and rising R&D costs make transformation urgent. The industry needs solutions now more than ever.
What is AI-QSP?
AI-QSP represents a revolutionary hybrid of mechanistic Quantitative Systems Pharmacology (QSP) combined with AI differential equations and QSP-GPT technology. This breakthrough transforms traditional 6–24 month model development cycles into continuously updated, interactive platforms that adapt in real-time.
01
Continuous Data Integration
Real-time incorporation of experimental and clinical data streams
02
Natural Language Access
QSP-GPT enables intuitive interaction for all team members
03
Regulatory-Ready Outputs
Compliant documentation and transparent decision-making
04
Scalable Development
Faster, more efficient model building across therapeutic areas
Key Differentiators
50% Faster & Cheaper
Dramatically reduced model build times and costs compared to traditional QSP approaches
Scalable Platform
Applies across oncology, immunology, neurology, and multiple therapeutic areas
Accessible Interface
Designed for non-specialists while maintaining scientific rigor
Regulatory-Grade
Built-in compliance with FDA and EMA Model-Informed Drug Development frameworks
Portfolio-Wide Impact
AI-QSP delivers transformative value across your entire pipeline. A 5–10% improvement in prediction accuracy can preserve multi-billion-dollar assets, while federated AI protects sensitive R&D data and enables dynamic team collaboration.
1
In Vitro
Cell models, dosing optimization, biomarker identification
2
In Vivo
Outcome prediction, refined dosing strategies
3
Preclinical
Candidate prioritization, toxicology assessment
4
Clinical
Protocol optimization, adaptive trial design
Financial Impact
£1M
Traditional QSP
Cost per model using conventional approaches
£0.5M
AI-QSP
Revolutionary cost reduction per model
£5M
Total Savings
For 10 models: £10M → £5M investment
Our 3-year implementation plan totals £5.4M, delivering net savings of £4–5M within 36 months through faster decisions and reduced attrition rates.
Founding Partner Privileges
Bespoke Models
Proprietary data integration and co-development teams
Priority Access
12–24 months earlier access than competitors
Regulatory Influence
Shape evolving frameworks as first movers
Exclusivity Options
Therapeutic-area exclusivity for strategic advantage
Strategic Opportunity
AI-QSP is especially attractive for Tier-2 pharma and specialist/regional companies lacking in-house capacity. This partnership offers the opportunity to leapfrog larger competitors by embracing AI-QSP early, gaining enterprise-wide advantages that extend far beyond traditional modeling tools.

Ready to Transform Your R&D?
Join as a Founding Partner and revolutionize your drug discovery pipeline with AI-QSP.
Contact: Contact: Prof. Igor Goryanin (goryanin@gmail.com) and Dr Oleg Demin (demin@insysbio.com)